Cell Death and Disease (Aug 2022)

FMRP modulates the Wnt signalling pathway in glioblastoma

  • Giorgia Pedini,
  • Mariachiara Buccarelli,
  • Fabrizio Bianchi,
  • Laura Pacini,
  • Giulia Cencelli,
  • Quintino Giorgio D’Alessandris,
  • Maurizio Martini,
  • Stefano Giannetti,
  • Franceschina Sasso,
  • Valentina Melocchi,
  • Maria Giulia Farace,
  • Tilmann Achsel,
  • Luigi M. Larocca,
  • Lucia Ricci-Vitiani,
  • Roberto Pallini,
  • Claudia Bagni

DOI
https://doi.org/10.1038/s41419-022-05019-w
Journal volume & issue
Vol. 13, no. 8
pp. 1 – 13

Abstract

Read online

Abstract Converging evidence indicates that the Fragile X Messenger Ribonucleoprotein (FMRP), which absent or mutated in Fragile X Syndrome (FXS), plays a role in many types of cancers. However, while FMRP roles in brain development and function have been extensively studied, its involvement in the biology of brain tumors remains largely unexplored. Here we show, in human glioblastoma (GBM) biopsies, that increased expression of FMRP directly correlates with a worse patient outcome. In contrast, reductions in FMRP correlate with a diminished tumor growth and proliferation of human GBM stem-like cells (GSCs) in vitro in a cell culture model and in vivo in mouse brain GSC xenografts. Consistently, increased FMRP levels promote GSC proliferation. To characterize the mechanism(s) by which FMRP regulates GSC proliferation, we performed GSC transcriptome analyses in GSCs expressing high levels of FMRP, and in these GSCs after knockdown of FMRP. We show that the WNT signalling is the most significantly enriched among the published FMRP target genes and genes involved in ASD. Consistently, we find that reductions in FMRP downregulate both the canonical WNT/β-Catenin and the non-canonical WNT-ERK1/2 signalling pathways, reducing the stability of several key transcription factors (i.e. β-Catenin, CREB and ETS1) previously implicated in the modulation of malignant features of glioma cells. Our findings support a key role for FMRP in GBM cancer progression, acting via regulation of WNT signalling.